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 ABSTRACT 
HIV-1 infection is characterized by persistent systemic inflammation and immune activation, 
even in patients receiving effective antiretroviral therapy (ART). Translocation of microbial 
compounds from a leaky gut to systemic circulation, so called microbial translocation (MT), 
is a major driver of the immune activation. Additionally, gut microbiota dysbiosis in HIV-1 
infected patients further facilitate and fuel MT.  
The objectives of this thesis were to study: 
 how different ART regimens and usage of antibiotics affect markers of MT (I, II) 
 the alternations of gut microbiota during HIV-1 infection and the effect of ART 
(III,IV) 
In a clinical randomized trial, HIV-1 infected subjects started ART based on efavirenz (n=37) 
or ritonavir-boosted lopinavir (n=34). Levels of MT markers and of enterocyte death were 
elevated at baseline (BL), and MT markers declined until follow up after 72 weeks, but the 
reduction of anti-flagellin IgG antibodies was significant only in lopinavir treated patients. 
Levels of Intestinal Fatty Acid Binding Protein (I-FABP) remained unchanged at 72 weeks, 
but were temporarily increased after one month in efavirenz treated patients. 29 subjects with 
concomitant use of antibiotics had superior reduction of soluble CD14 (sCD14) levels. These 
data show that choice of ART and antibiotics usage could affect the kinetics of some MT 
markers. 
To further explore the impact of antibiotics usage on MT, we performed a longitudinal study 
on HIV-1 patients initiating ART without (n=13) or with (n=13) co-trimoxazole (TMP-SMX) 
as prophylaxis against Pneumocystis jirovecii. Following ART, levels of LPS-binding protein 
(LBP) were reduced only in the TMP-SMX group, whilst levels of sCD14 declined in both 
groups after one year. The LBP decrease remained significant in a multivariate analysis 
model adjusting for co-variates including BL CD4+ T-cell count. This study confirmed that 
concomitant use of antibiotics and ART in severely immune deteriorated individuals may 
beneficially influence the kinetics of MT markers. 
In the third study, the composition of gut microbiota was determined by 16S rRNA 
sequencing in 28 HIV-1 progressors, 3 Elite controllers (EC) and 9 uninfected controls at BL, 
and additionally after ten months of ART in 16 subjects. Gut microbiome α-diversity was 
reduced in HIV-1 infected individuals as compared to controls, and further declined after 
introduction of ART. At BL, α-diversity was positively correlated with CD4+ T-cell counts, 
but in contrary several markers of MT/immune activation were inversely correlated. 
Microbiome of EC had the lowest interindividual variation (ß-diversity), clustering together 
in PCoA analysis. The bacterial composition at genus level was altered in HIV-1 progressors 
with higher abundance of Lactobacillus, and depletion of Lachnobacterium, 
Faecalibacterium and Hemophilus. Thus, this study showed that the alternations of gut 
 microbiota during HIV-1 infection are associated with the level of immune dysfunction, and 
that almost one year of ART does not restore the shifts in the gut microbiome. 
In the last work, we studied the gut microbiome of 16 EC in relation to 32 matched ART 
naive HIV-1 positive individuals and 16 uninfected controls. The number of observed genera 
and richness indices Chao-1 and ACE were significantly higher in EC as compared to naive 
patients. The gut microbiota in EC was enriched in genera Succinivibrio, Sutterella, 
Rhizobium, Delftia, Anaerofilum and Oscillospira, whilst Blautia and Anaerostipes were 
reduced. Determination of inferred bacterial functionality by PICRUSt analysis revealed that 
carbohydrate metabolism related genes were depleted in EC. In contrary, pathways related to 
fatty acid metabolism, PPAR-signaling and lipid biosynthesis proteins were more abundant in 
EC vs naive. The kynurenine pathway of tryptophan metabolism was altered only during 
progressive HIV-1 infection, and kynurenine tryptophan (K/T) ratio was inversely associated 
with gut microbiota richness. This study shows that EC have richer gut microbiota than 
untreated HIV-1 patients with progressive infection, with a unique bacterial composition and 
a distinct metabolic profile which may be involved in the control of HIV-1. 
In summary, data from the studies in my thesis reveal that MT in HIV-1 infection is reduced 
by ART but also that the choice of ART influences this decline. Additionally, the antibiotics 
usage may affect the levels of MT. The complexity, composition and functionality of gut 
microbiota are disturbed in HIV-1 infected individuals with progressive disease, whilst EC 
have a unique gut microbiota profile that eventually contributes to their control of HIV-1.    
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 1 
1 INTRODUCTION 
 
Since the appearance of the human immunodeficiency virus (HIV) epidemic, tremendous 
progress has been achieved in the treatment and care of HIV infected patients. The 
breakthrough with highly active antiretroviral therapy (HAART) at 1995-96 dramatically 
decreased AIDS related mortality and reduced prevalence of HIV related conditions. A 
systemic immune activation was early identified as a hallmark of HIV-1 infection in 
untreated patients and this feature persists even in patients treated with combined 
antiretroviral treatment (ART), regardless of undetectable plasma viral load. The chronic 
immune activation and inflammation contribute to a higher risk of both AIDS related 
clinical events and to non-AIDS related conditions
1,2
. Following initiation of ART, the 
levels of both cellular and serum biomarkers of immune activation are thus reduced, but not 
to the levels present in healthy controls
3,4
. 
There are several potential contributors fueling the low-grade inflammation, in addition to 
HIV itself. Co-infections with other viruses inducing an inflammatory response like 
cytomegalovirus, Epstein-Barr virus and hepatitis B/C may further maintain the 
inflammatory state
5-7
. Other microbial triggers, like protozoan parasites may contribute to 
additional inflammation. Thus, in endemic areas, co-infections with malaria and visceral 
leishmaniasis in HIV patients represent independent causes of intensive immune 
activation
8,9
. Moreover, translocation of bacteria or bacterial products across a damaged 
gut-blood barrier, so called microbial translocation (MT), has been proposed to be one of 
the most important mechanisms behind the chronic immune activation in HIV infection
10
.
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2 BACKGROUND 
2.1 HIV CHARACTERISTICS 
HIV is a lentivirus within the Retroviridae family, which infects host cells expressing the 
CD4 receptor, e.g. lymphocytes, monocytes, dendritic and microglia cells. In addition, an 
interaction with the co-receptors CCR5 or CXCR4 is crucial for viral cell entry
11
. By using 
the viral enzymes reverse transcriptase (RT) for generation of double-stranded DNA from the 
viral RNA templates, followed by integration of this proviral DNA into the human 
chromosomes by HIV integrase, a viral reservoir is established in the human genome. This 
persistent reservoir is formed very early during the acute infection in the resting memory 
CD4+ cells
12
. Also other cellular reservoirs exist, such as the pool of macrophages and 
follicular dendritic cells
13,14
. The viral replication rate is intensive with 10
10-11 
virions 
produced every day
15
, and together with the inborn high error rate of the RT during the DNA 
synthesis, an enormous viral diversity develops. 
Two different types, HIV-1 and HIV-2, infect humans and cause HIV related disease 
followed by AIDS, if untreated, when the function of the immune system has become 
severely deteriorated. HIV-1 is phylogenetically classified into several groups: (I) the 
worldwide spread M (major) group, representing >90% of all HIV infections, which can be 
further subdivided into 9 subtypes (A-D, F-H, J, K) and circulating recombinant forms 
(CRFs); (II) N; (III) O and (IV) P. Also unique recombinant forms exist
16
. HIV-2 is 
categorized into groups A-H
17,18
. 
The clinical course varies between the two HIV types. Typically, AIDS defining conditions 
and complications related to HIV-1 infection present 8-10 years after transmission, but a 
smaller proportion of the patients have an accelerated disease progression already after 
seroconversion over a period of 2-3 years
19
. The disease progression is slower in HIV-2 
infected, and development of low CD4+ T-cell counts complicated by opportunistic 
infections may be deferred for 20 (-30) years
20,21
. The plasma HIV-2 load is usually very low 
or undetectable during the asymptomatic course in these patients
22
, similar to the HIV-1 
infected Elite controllers who are able to spontaneously maintain viral plasma suppression 
without ART for decades
23
. 
2.2 EPIDEMIOLOGY 
In the 2016 UNAIDS Global AIDS update, an estimated 36.7 million individuals are living 
with HIV, of whom ~17 million are on ART at the end of 2015
24
. HIV-1 is responsible for 
most of the global HIV burden. The overall prevalence of HIV-2 infections is low world-
wide, and a total of 1-2 million people are expected to be HIV-2 positive. Anyhow, the 
estimated HIV-2 seroprevalence is 1-5 % in some countries in West Africa, with significant 
proportions of patients being dually infected with HIV-1
25,26
. 
In Sweden, the number of diagnosed people living with HIV was 20
th
 of June 2017:7338,  
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according to the Swedish InfCare HIV quality assurance registry, with 430 newly diagnosed 
cases in 2016. This corresponds to a prevalence of ~0.07%, which is one of the lowest in 
Europe
27
. During the last five years, 15-25% of the newly diagnosed patients contracted HIV 
in Sweden according to reports from treating physicians. However recent data suggest that at 
least 20% of migrants are infected after arrival to our country
28
. 
 
2.3 HIV-1, IMMUNE ACTIVATION AND INFLAMMATION 
HIV-1 infection is associated with activation of both the innate and adaptive parts of the 
immune system. An extensive systemic immune activation starts immediately at acute 
infection
29
, but gradually decreases during the chronic phase, though still present at 
abnormally high levels
30,31
. Even in well treated patients with undetectable plasma viral load, 
a chronic immune activation and low-grade inflammation are found
32
. 
 
 
 
Figure 1. Factors associated with immune activation during HIV-1 infection. 
 
Several components of the innate immune system are activated in HIV-1 infection. The 
myeloid dentritic cells (mDCs), presenting processed antigens to T-cells in lymph nodes with 
subsequent T-cell activation, as well as interferon-γ producing plasmacytoid dendritic cells 
(pDCs) display transcriptional profiles associated with immune activation in vivo
33
. Enteric 
mDCs become activated by mucosal bacteria like Prevotella, which may lead to both local 
and systemic immune activation
34
. Activation of monocytes/macrophages is represented by 
4 
 
increased systemic levels of sCD14, sCD163
35-37
 and inflammatory cytokines (TNF-α, 
interleukin (IL)-1 and IL-6)
38,39
. Also the neutrophils are activated with high surface 
expression of program death ligand 1 (PD-L1), and with upregulation of TNF-α and IL-6 
production
40,41
. Furthermore, overexpression of activation markers on natural killer (NK) 
cells with reduced cytolytic capacity has been reported in HIV-1 infection
42
. 
The cellular immune activation during HIV-1 infection has been extensively explored, and T-
cell activation markers may predict disease progression in untreated patients
43
. Persistent 
activation of CD4+ and particularly CD8+ T-lymphocytes is evident in the vast majority of 
naive patients
4,30
. Common cellular markers of immune activation include surface expression 
of HLA-DR and CD38. The CD4/8 T-cell ratio is also a useful tool for indirect prediction of 
immune activation
44
. 
The magnitude of CD8+ T-cell immune activation early during HIV-1 infection may predict 
the CD4+ cell decline independent of the viral load
45
. It has been assumed, that most CD4+ 
T-cells will undergo apoptosis secondary to exhaustion and senescence caused by the 
activation
46
. ART partially reverses this process, but does not fully restore the CD4+ T-cell 
dysregulation and function
47
. Recently, another mechanism behind loss of CD4+ T-cells has 
been elucidated. Depletion of these cells by pyroptosis, a process where the pool of resting 
CD4+ cells (~95% of the CD4+ T-lymphocytes) die bycaspase-1 programmed cell death 
seems to be the major cause behind the loss of CD+ T-cells in HIV-1 infection
48
. This way of 
cell death is associated with release of pro-inflammatory cytokines like IL-1ß, resulting in an 
intensive inflammatory reaction. The pyroptosis takes place mainly in lymphoid tissue, and 
CD4+ T-cells in blood seems to be highly resistant to this type of cell death
49
. Development 
of liver fibrosis has been associated with this pathway of cell death
50
, and the fibrosis in 
lymphatic tissues observed in HIV-1 infection may be related to this type of inflammatory 
cell death.  
Defects in the B-lymphocyte line may further fuel the inflammation in HIV-1 infection. 
Memory B-cells have a lower quality of response to HIV in infected subjects
51
, and also 
decreased IgA and IgG responses have been demonstrated
52
. HIV-specific antibody responses 
are improved by ART, but the overall frequencies of HIV-specific B cells remain abnormally 
low
51
. 
Increased activity in the kynurenine pathway of tryptophan catabolism, mediated by the 
enzyme indoleamine 2,3-dioxygenase 1 (IDO1), has been considered to be another important 
factor behind the chronic inflammation in HIV infection. IDO1 overactivity in HIV-infection 
may influence the ratio between gut resident regulatory T-cells and Th17+ cells
53
. This leads 
to a progressive injury of the epithelial mucosal barrier, followed by increased MT and 
immune activation
54
. 
The chronic immune activation causes a low grade inflammation that persists after initiation 
of ART, and several soluble systemic markers of inflammation are elevated. Typically, 
increase of CRP, IL-1, IL-6 and TNF-α is observed. Additionally, the coagulation system is 
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disturbed with elevated levels of D-dimer, tissue factor and von Willebrand factor. The 
alternations in the inflammation and coagulation cascades contribute to the HIV related 
complications from the cardiovascular system, musculoskeletal system, end-organ disease in 
e.g. liver and kidney, malignancies, neurocognitive impairment and accelerated aging
2
. 
2.4 MICROBIAL TRANSLOCATION 
The human gut compartment represents the largest lymphoid organ in the body, and the 
intestinal mucosa is constantly exposed to external microorganisms. It plays an important role 
for maintaining the immunological homeostasis, mediated through innate and acquired 
immunological responses
55
. Gut associated lymphoid tissue (GALT) consists of mesenteric 
lymph nodes, Peyer´s patches in the small intestine, and follicular aggregates in the large 
intestine
56
. The mucus layer in the gastrointestinal (GI) tract, consisting of proteins, 
phospholipids, electrolytes, water, secretory IgA and antimicrobial peptides, forms a 
physiological barrier against pathogenic microorganisms. Intraluminal granulocytes maintain 
control from commensal bacterial overgrowth, and submucosal macrophages and 
lymphocytes eliminate bacteria or bacterial products crossing the structural parts of the 
intestinal wall. This is based upon lined enterocytes, closely connected with tight junctions 
(intercellular structures that join GI-epithelial cells firmly together). All these parts form a 
complex construction, termed the gut-blood barrier. It strictly regulates both passive and 
active transfer of fluid, nutrients and electrolytes. In HIV-1 infection, most of the different 
anatomical and physiological parts of the gut-blood barrier are abnormal, as reviewed by 
Sandler and Douek
57
. 
The term microbial translocation (MT) refers to translocation of gut resident intraluminal 
commensal microbial products into systemic circulation without manifest bacteremia. 
Translocating microbial compounds from bacteria include peptidoglycans from the cell 
wall
58
, lipopolysaccharide (LPS) from the outer cell membrane of gram-negative bacteria
10
, 
flagellin
59,60
 and bacterial DNA
61
. Also viral RNA/DNA
62
 and ß-glucans from bacterial or 
fungal organisms may cross the blood-gut barrier
63
. MT has been linked to a spectrum of 
diseases besides HIV. It has been described e.g. in patients with inflammatory bowel disease 
(IBD)
64
, coeliac disease
65
,  infectious and alcoholic cirrhosis
66-68
, hepatitis B/C virus 
infection
66,69
, and during Dengue infection
70
. Diseases that are characterized by systemic MT 
are often associated with shifts in the gut microbiota composition. 
2.5 MARKERS OF MICROBIAL TRANSLOCATION 
There are numerous established markers of MT. Anyhow, to find appropriate tools and 
markers to estimate the magnitude of MT has been associated with several difficulties. The 
traditionally most widely used marker is LPS, a major component of the monolayer of outer 
cell membrane in most gram-negative bacteria. Thus, it is a direct marker of bacterial 
products translocating to the systemic circulation. The structure of LPS varies between 
different bacteria, and the innate immune response may differ 100-fold depending on type of 
bacterial trigger. LPS forms a complex with LPS-binding protein (LBP), membrane 
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associated or soluble CD14, MD-2 and toll-like receptor 4 (TLR4) on the surface of innate 
immune cells, preferentially monocytes and macrophages. This starts a cascade of 
intracellular processes, mediated via several pathways, whereof activation of the transcription 
factors nuclear factor kappaB (NFκB) and activator protein-1 (AP-1) are the most 
important
71
. The subsequent gene expression results in production of inflammatory cytokines 
like interleukins, TNF-α and interferons72,73 (Figure 2). 
 
 
 
 
Figure 2. LPS/TLR4 complex related intracellular signaling pathways.  
Adapted from: Scavenger receptor SREC-I mediated entry of TLR4 into lipid microdomains and triggered inflammatory cytokine release in 
RAW 264.7 cells upon LPS activation. Murshid A, Gong J, Prince T, Borges TJ, Calderwood SK. PLoS One. 2015 Apr 2;10(4):e0122529. 
doi: 10.1371/journal.pone.0122529. eCollection 2015. 
Although LPS has been considered to be the most established marker of MT, the analysis 
process of this marker is associated with technical issues. There is variability between 
different limulus lysate assay test kits (standard for LPS detection), but also inter-run 
variability lowers the validity of results. Additionally, the non-fasting condition at sampling 
can affect LPS levels, and endogenous circulating proteins may inhibit or degrade systemic 
LPS. 
Another direct marker of MT is systemic bacterial DNA. Traditionally, plasma PCR of the 
conserved 16S ribosomal DNA (16SrDNA) region with Sanger sequencing has been used. 
Anyhow, the sensitivity and specificity of the method are uncertain with some studies 
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showing elevated levels of 16SrDNA in HIV positive compared to negative individuals
61,74
, 
in opposite to others
75,76
. Utilizing next generation sequencing (NGS) for characterization of 
systemic bacterial DNA may enhance the diagnostic accuracy, as discussed by Svärd et al
76
. 
Several indirect markers of MT are used. LPS-binding protein (LBP) is an acute phase 
protein, mainly produced in liver and to a smaller extent in pulmonary, gastrointestinal and 
kidney epithelial cells
77-79
. It is mostly released upon LPS stimuli, but induction may also be 
triggered by other microbiological structures. Peptidoglycans from gram-positive bacteria and 
β-glucans from fungal organisms are molecules also recognized as LBP inducers80. 
Membrane bound CD14 is a pattern recognition receptor found mainly on macrophages, 
recognizing LPS from gram-negative bacteria, peptidoglycans and lipoteichoic acid from 
gram-positive bacteria, and lipoproteins from spirochetes
81
. Shedding of the membrane bound 
CD14 gives the soluble form sCD14, which acts as a marker of monocyte activation upon 
mainly LPS stimuli, thus appropriate as an indirect marker of MT. Anyhow, HIV itself and a 
broad spectrum of other microbial agents like Dengue, RSV, and Mycobacteria are known 
triggers of sCD14 production, which has to be considered when interpreting sCD14 
results
70,82,83
. 
Intestinal fatty acid binding protein (I-FABP) is released by enterocytes undergoing cell 
death, and elevated levels reflect damage to the small intestinal cells. As the enterocytes have 
a high turnover rate, high plasma I-FABP levels indicate an elevated loss of enterocytes 
followed by abnormally high intestinal permeability
84
. Elevated levels of I-FABP have been 
linked to inflammatory bowel diseases, septicemia and also following abdominal surgery
85,86
. 
Detection of antibody responses against the bacterial antigen flagellin has been studied in 
patients with IBD (anti-CBir1)
87
 and in patients with HIV/AIDS (anti-CBir1, anti-flagellin 
antibodies)
88,89
. Both antibodies are of IgG type, and may provide insights of the degree of 
MT over a prolonged period of time due to their long half-lifetime. 
 
2.6 MICROBIAL TRANSLOCATION IN HIV-1 INFECTION 
A rapid depletion of mucosal CD4+ T-cells, preferentially affecting the subpopulation of 
Th17+ T-cells in GALT, starts very early after acquisition of HIV
90
. The IL-17 and IL-22 
producing Th17+ cells have essential immunological properties, and are important for the 
homeostasis of epithelial cells. They produce antimicrobial peptides like defensins, support 
recruitment of neutrophils on response to intraluminal pathogenic bacteria and fungi, and 
enhance proliferation of enterocytes
91-94
.  
Furthermore, the structural integrity of the barrier in GI-tract is impaired due to the HIV 
infection, leading to a disruption of the epithelial barrier. This is caused by an increased 
turnover rate of enterocytes and destruction of the important tight junctions starting within the 
first weeks post-infection
95
. Following oral challenge with lactulose/L-rhamnose, an 
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increased urine excretion was observed in 20% of asymptomatic HIV patients, and in vast 
majority of AIDS patients, reflecting the enhanced intestinal permeability
96
. In the early HIV-
era, villous atrophy was observed in patients with wasting syndrome
97
, with subsequent 
malabsorption of carbohydrates, proteins, fat and nutrients such as zink and iron. 
Abnormally low intraluminal IgA-concentrations due to B-cell dysfunction with decreased 
proportion of mucosal plasma cells has been associated to HIV infection
98
.  Secretory IgA 
prohibits intraluminal microbes from attachment to and translocation across the epithelial 
barrier. The local IgA-deficiency may further contribute to less capacity of neutralizing 
microbial products (Figure 3). 
Figure 3. The pathogenesis of HIV-1 induced gut damage. During HIV-1 infection, CD4+ T-cells are lost, and CD8+ T-cells are activated 
in the submucosal parts of the gut. This is associated with an increased turnover of enterocytes, loss of tight junctions (connecting the 
epithelial cells strictly together), impaired recruitment of neutrophils and less production of antimicrobial peptides. Additionally, the B-
lymphocytes are dysfunctional, and intraluminal IgA concentration is lowered. As a consequence, microbial parts may translocate from gut 
lumen into systemic circulation, triggering the immune system and contributing to chronic immune activation.  
The clearance of MT products from systemic circulation takes place mainly in the liver, 
delivered via the portal vein. Hepatocytes and specialized liver resident macrophages, 
(Kupffer cells), which are activated by an innate immune response via TLR4-CD14 complex 
upon LPS-stimuli, clear most of enteric derived LPS
99
. Kupffer cells are depleted in HIV-
hepatitis C co-infection
100
, and serum markers of MT have been elevated compared to 
hepatitis C mono- infected
101
. These data suggest that MT may play an important role in the 
more rapidly developed fibrosis progress and cirrhosis observed in co-infected patients. 
Phagocytosis by mucosal macrophages is another crucial mechanism to clear translocating 
microbial products. In a study of simian immunodeficiency virus (SIV) infected rhesus 
macaques, Estes et al
95
 showed that intestinal macrophages have impaired phagocytic 
capability, and instead a dysfunctional response on translocating bacterial products is 
observed, with secretion of inflammatory cytokines. Similar findings have been reported in 
HIV infected patients, where density of mucosal macrophages was higher, but their 
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phagocytic skills were impaired
102
. Altogether, these defective compounds involved in human 
defense against microbial products invading from the intestinal lumen contribute to the leaky-
gut syndrome featuring HIV infection. 
2.7 MICROBIAL TRANSLOCATION AND ANTIRETROVIRAL THERAPY 
ART reduces markers of systemic T-cell activation, but there are conflicting data about the 
effect on MT. The choice of surrogate MT marker will most likely impact the interpretation 
of the magnitude of MT. Also co-morbidities, nadir CD4+ cell count, timing and duration of 
ART may influence level of MT after initiation of ART. Moreover, concomitant use of 
antibiotics probably may influence some of MT markers, e.g. LPS, LBP and sCD14. Most 
studies report declining LPS levels after ART initiation
10,103,104
, while no reduction was 
observed in other studies
35,105-107
. This may partly be explained by the different techniques 
and kits used for determination of the LPS levels, with associated difficulties of measuring 
LPS. Anyhow, when the more stable marker sCD14 is used, results are still diverging, with 
some presenting declining
35,105,108
 or increasing levels
104,106
 after introduction of ART. The 
trend is the same for most of the other surrogate markers, with the exception of LBP, that 
seems to decline in most of the studied HIV cohorts after starting ART
109,110
. Two studies on 
early initiation of ART during acute HIV infection did not demonstrate any positive effect on 
levels of MT markers
111,112
, although this might be due to that ART was started before any 
significant MT had developed. Such an interpretation is supported by a recent article, where 
the introduction of ART during acute HIV infection was associated with less immune 
activation and inflammation in colonic lamina propria at 24 weeks. Though, a significant 
reconstitution of CD4+ T-cells was observed in only blood and not in the sigmoid biopsies 
even after 96 weeks
113
. These data illustrate the difficulties of interpreting how organ-specific 
and systemic immune destruction and recovery are connected with inflammation and immune 
activation related to MT.  
The impact of the individual components in a HIV drug regimen is less explored. Some 
minor differences in the levels of monocyte activation markers have been observed, with 
higher sCD14 in patients on NNRTI + boosted protease inhibitors (PI), but without affecting 
the overall magnitude of MT
114
 . Interestingly, monotherapy with PI has also been linked to 
higher levels of monocyte activation markers (sCD14, sCD163), but still levels of LBP did 
not diverge from patients with standard ART, thus not indicating increased MT, so other 
mechanisms than MT may trigger the innate immune activation during PI monotherapy 
115
. In 
another cross-sectional study from Mexico, it was reported that the levels of sCD14 and I-
FABP were elevated in patients on long-term ART based on boosted atazanavir or lopinavir, 
but not in efavirenz treated subjects
116
. All together, these findings raise concerns about the 
insufficient effects of monotherapy with protease inhibitors. In contrast, viral reservoirs were 
found to be smaller in patients on NNRTI based ART
117
, and the size of the gut reservoir has 
been linked to MT
118
. To summarize, the effect of specific ART regimens and the individual 
drugs on MT during chronic HIV infection is uncertain, and has to be further investigated in 
larger scaled, preferable randomized studies. 
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2.8 THE HUMAN GUT MICROBIOTA 
The total bacterial number in the adult human gut has traditionally been estimated to be 
~10
14
, composed by 500-1000 different species, together creating an estimated biomass of 1.5 
kg
119,120
. The vast majority of the commensal bacteria in the gut resides in the colon, and only 
small fractions are located in the stomach and the small intestine. Though, in a recent paper 
the number of enteric bacteria was calculated to be ~4x10
13
, suggesting that the commonly 
accepted bacteria to human cell ratio 10:1 is much closer 1:1
121
. Bacteroides, Clostridium, 
Lactobacillus, Fusobacterium, Bifidobacterium, Eubacterium, Peptococcus, 
Peptostreptococcus, Escherichia and Veillonella are the most abundant genera forming the 
commensal gut flora
122
. The human gut microbiome has many crucial biological functions. 
This bacterial compound facilitates absorption and digestion of nutrients, and also 
biosynthesizes vitamins like biotin, thiamine and folate. Short-chain fatty acids (SCFA), such 
as butyrate, propionate and acetate, are of major importance for maintaining the gut 
homeostasis as they serve as both energy sources for endothelial cells and as signaling 
molecules
123
. They are produced by commensal Clostridia and Lactobacillales species, as 
products of fermentation of dietary fibers and end products from carbohydrates
124
. 
Additionally, the microbiome also confers resistance against invasion of pathogenic bacteria, 
and interferes with the host’s production of antimicrobial peptides. Importantly, it is also 
deeply involved in development and modulation of the immune system
125
. Early in life, gut 
colonization with lactobacilli during first two months after birth has been associated with a 
favorable cytokine pattern at the age of two years, suggesting that specific bacterial species 
may affect subsets of T helper cells
126
. 
 
2.9 GUT MICROBIOTA IN HIV-1 INFECTION 
The influence of HIV infection on gut microbial flora was first elucidated in 2008 when the 
composition of gut microbiome was assessed by fluorescence in situ hybridization and 
quantitative real-time PCR for Pseudomonas on fecal samples from 57 asymptomatic and 
ART naïve HIV patients. The presence of Pseudomonas aeruginosa was 92% in HIV 
infected vs 20% in healthy subjects, corresponding to a 10-fold increase of the Pseudomonas 
proportion of total microbiota. Further, Candida albicans was detected in all samples from 
the HIV infected, compared to 40% from the healthy population
127
, advocating a pathological 
shift in the composition of the microbial gut flora during HIV infection. Determination of gut 
microbiome with quantitative molecular techniques was first presented in a pilot study by 
Ellis et al, demonstrating that total bacterial load analyzed by 16SrDNA PCR was lower and 
the proportion of order Enterobacteriales was higher in stools of treatment naïve HIV 
infected compared to uninfected individuals. Additionally, the CD4+ cell count in duodenal 
tissue correlated negatively with the fraction of Enterobacteriales, and the total bacterial load 
was also negatively correlated to activation of CD4/8+ cells in duodenal tissue
128
, 
highlighting the importance of the gut microbiome composition as a functional trigger of 
chronic systemic immune activation. Since then, several studies using NGS have shown a 
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higher abundance of Proteobacteria and depletion of Firmicutes at phylum level in HIV+ 
populations
129-131
. More frequently, enrichment of genus Prevotella and depletion of 
Bacteroides has been reported in fecal samples
132,133
 or gut mucosal tissue
130,134
 of untreated 
chronically HIV infected subjects. Multiple bacterial species involved in production of short-
chain fatty acids, e.g. butyrate, are less represented in the fecal flora of HIV+ subjects. 
Proportions of Faecalibacterium spp., Eubacterium spp. and Coprucoccus spp. have been 
reduced in several cohorts
130,134,135
. This may influence the turnover of epithelial cells, and 
affect the tuning of immunological mucosal cells. In the complex interplay between 
intraluminal microorganisms and GALT, beneficial commensals like Lactobacillales and 
Bifidobacteria have been linked to mucosal anti-inflammatory properties
136
. The relative 
amount of both taxa is lowered in fecal flora from an HIV infected population
127,134
, and 
dietary supplementation with prebiotics has been shown to partially restore the shortage
137
.  
In a randomized trial comparing ART plus maraviroc versus placebo, the systemic and gut 
CD4+ cell counts were positively correlated to the rectal proportions of Lactobacillales. 
Additionally, higher proportions of Lactobacillales were associated with less MT in these 
treatment naïve patients, further indicating the protective qualities of these bacteria. In this 
longitudinal study, subjects were followed after initiation of ART, and the percentage of gut 
CD4+ cells correlated to the proportions of Lactobacillales after 48 weeks
138
, indicating that 
recovery of the immune system may be due to the interaction between ART and the fraction 
of beneficial commensals. According to a recent exploratory work by Dinh et al, where the 
fecal microbiota from 21 HIV patients on suppressive ART for in median 13 years was 
profiled, the composition differed significantly from healthy controls. Enrichment of 
Proteobacteria, Gammaproteobacteria, Enterobacteriales, Enterobacteriaceae, Erysipelotrichi, 
Erysipelotrichales, Erysipelotrichaceae and Barnesiella was found in HIV+ individuals
139
, 
and the abundance of pathogenic organisms correlated to markers of MT and systemic 
inflammation. Thus, dysbiosis of gut microbiota with related MT and immune activation 
seems to persist for more than a decade even with fully suppressive ART, but 
supplementation with pre/probiotics may be possible therapeutic strategies. The choice of 
ART regimen may also be of importance, as only a combination of 2 NRTIs + integrase 
inhibitor was able to restore the diversity loss and systemic inflammation in a cross-sectional 
study on HIV-1 patients. But still, in this work no major shifts in the gut microbiome were 
observed at phylum level before or after initiation of ART
114
. 
2.10 ELITE CONTROLLERS 
Elite controllers (EC) constitute a unique subset of HIV-1 infected individuals with the ability 
to spontaneously control the HIV-1 replication over time without ART, representing less than 
1% of the total HIV-1 population
23
. Until today, there has been sparse data about MT in this 
group of HIV-1 patients. In the pioneering work by Brenchley et al, EC demonstrated higher 
levels of LPS compared to uninfected controls, but levels tended to be lower than in the HIV-
1 progressors
10
. This finding was confirmed by Hunt et al, who investigated 30 EC, and 
found that the proportion of activated (CD38+ HLA-DR+) CD4+ and CD8+ cells were 
higher compared to both HIV-1 negative individuals and patients virologically suppressed by 
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ART. The plasma LPS levels were also significantly elevated in EC compared to HIV 
negative controls, consistent with gut MT
140
. Later on, the number and proportion of CD17+ 
T-cells in gut biopsies from EC have been shown to be similar to HIV-1 negative 
individuals
141
. In a recent study from Kim et al
142
, four EC with a median duration of HIV-1 
infection for 18.5 years did have similar plasma levels of LPS and sCD14 at baseline as HIV 
negative controls, thus without evidence of increased MT in these EC. The blood CD8+ T-
cell activation was also similar in both groups, but the CD4/CD8 ratio was lower in EC 
compared to HIV negative controls, and higher levels of D-dimer and IL-6 were observed in 
EC. All EC received ART for 6 months, but did not normalize their levels; nevertheless 
CD4/CD8 ratio was positively affected. Interestingly, a reduction of the mucosal Th17+ cell 
polyfunctionality was observed after ART discontinuation, but no long-term follow up of MT 
was performed in order to search for a progressive MT. In a Brazilian cohort, 7 EC and HIV 
negative controls were found to have comparable sCD14 levels, but in EC with occasional 
viremic episodes (<30% of frequency of transient viremia between 81 and 400 copies per 
mL), sCD14 levels were significantly higher compared to healthy controls
143
. Taken these 
divergent data together, further studies of MT in EC are warranted. 
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3 AIMS 
The general aim was to assess the MT and the composition of gut microbiota in HIV-1 
infection. Additionally, we wanted to explore the influence of antiretroviral therapy and 
antibiotics on MT. 
Study I 
Vesterbacka Jan, Nowak Piotr, Barqasho Babilonia, Abdurahman Samir, Nyström Jessica, 
Nilsson Staffan, Funaoka Hiroyuki, Kanda Tatsuo, Andersson Lars-Magnus, Gisslèn 
Magnus, Sönnerborg Anders. Kinetics of microbial translocation markers in patients on 
efavirenz or lopinavir/r based antiretroviral therapy. PLoS One. 2013;8(1):e55038 
The aim was to examine how levels of MT markers were longitudinally affected up to 72 
weeks after initiation of two different ART regimens in HIV-1 infected individuals, and to 
investigate the influence of antibiotics use on MT. 
Study II 
Vesterbacka Jan, Barqasho Babilonia, Häggblom Amanda, Nowak Piotr. Effects of Co-
Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating 
Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2015 Aug;31(8):830-6 
The aim was to determine the levels of MT markers in HIV-1 patients initiating ART with or 
without co-trimoxazole (TMP-SMX) prophylaxis. 
Study III 
Nowak Piotr, Troseid Marius, Avershina Ekatarina, Barqasho Babilonia, Neogi Ujjwal, 
Holm Kristian, Hov Johannes R, Noyan Kajsa, Vesterbacka Jan, Svärd Jenny, Rudi Knut, 
Sönnerborg Anders. Gut microbiota diversity predicts immune status in HIV-1 infection. 
AIDS. 2015 Nov 28;29(18):2409-18 
The aim was to investigate the diversity and composition of gut microbiota in treatment naive 
HIV-1 patients, and to examine the relation between gut microbiota and immune status. 
Additionally, we studied the effect of ART after one year. 
Study IV 
Vesterbacka Jan, Rivera Javier, Noyan Kajsa, Parera Mariona, Neogi Ujjwal, Calle Malu, 
Paredes Roger, Sönnerborg Anders, Noguera-Julian Marc, Nowak Piotr. Richer gut 
microbiota with distinct metabolic profile in HIV infected Elite Controllers. Sci Rep. 2017 
Jul 24;7(1):6269. doi: 10.1038/s41598-017-06675-1 
The aim was to explore the composition and functionality of gut microbiota in EC as 
compared to HIV-1 infected patients with progressive disease. 
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4 METHODS 
4.1 SUBJECTS 
 
Paper I 
In a Scandinavian randomized clinical phase IV efficacy trial (RCT) trial (NORTHIV), 239 
ART naïve HIV-1 infected subjects received allocated intervention. In our substudy, the 
patients were randomized to ART with either the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) efavirenz (EFV) + 2 nucleoside reverse transcriptase inhibitors (NRTIs) 
once daily (n= 37), or ritonavir-boosted lopinavir (LPV) + 2 NRTIs twice daily (n= 34). 
Plasma was collected at baseline (BL) and after 72 weeks (w72). Data on antibiotic therapy 
was available in 63/71 patients, of whom 29 received antibiotics at BL (n= 27) and/or w72 
(n= 10), while 34 had not been given antibiotics at any of the two time points.  
Paper II 
Patients with HIV-1 infection (n= 26) followed at the Department of Infectious Diseases, 
Karolinska University Hospital, Stockholm, Sweden, who initiated first line ART, were 
selected from a larger cohort based on sample availability. They were classified into two 
groups dependent on whether they started ART and concomitantly TMP-SMX prophylaxis 
against Pneumocystis jirovecii (160mg/800mg three times a week) (n= 13) or not (n= 13). 
Plasma was collected at first visit at the clinic (BL), at one month (FU1) and after one year 
(FU2). TMP-SMX was started in median 7 days (IQR 1.5-21) and ART 12 days (7.5-15) 
after BL. In the non-TMP-SMX group ART was initiated 21 days (8.5-52) after BL. ART 
consisted of two NRTIs: tenofovir (n=15), abacavir (n=6) or zidovudine (n=4) in combination 
with lamivudine/emtricitabine, and the NNRTI efavirenz (n=7) or one of ritonavir boosted 
protease inhibitors (PI/r) LPV (n=8), darunavir (n=4) or atazanavir (n=6), with exception of 
one patient in the group of ART only who was treated with the integrase inhibitor raltegravir 
+ darunavir/r. 
Paper III 
An observational cohort of 31 HIV-1-infected individuals was recruited from the HIV 
Outpatient Clinic at Karolinska University Hospital, Stockholm, Sweden. Additionally, a sex 
and age-matched control group of nine healthy HIV-1-seronegative individuals was included. 
Stool and peripheral blood samples were collected from all study participants at baseline and 
for 19 patients at follow-up (median 10 months; interquartile range 4–15) after ART 
introduction. ART consisted of two NRTIs in combination with a NNRTI (n=8) or a PI/r 
(n=11). Neither patients nor controls had been prescribed antibiotics or consumed probiotics 
during the preceding 2 months, or had infectious diarrhea. 
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Paper IV 
Totally, 48 HIV positive subjects and 16 HIV negative controls were recruited from the out-
patient HIV clinic at Karolinska University Hospital, Stockholm, Sweden. All viremic 
progressors were ART naive (naive). Exclusion criteria were inflammatory bowel disease or 
infectious gastroenteritis within the last four weeks. EC were defined by: (I) HIV positive for 
≥ 1 year and with ≥ 3 consecutive viral loads (VLs) <75 c/ml over one year with all previous 
VLs <1000 c/m, or (II) HIV positive for ≥ 10 years, with ≥ 2 VLs and ≥ 90% of all VLs <400 
c/ml. The study subjects were categorized into three groups (EC: n=16; naive: n=32; 
negative: n=16) and matched by Body Mass Index (BMI), age, gender and sexual practice. 
Plasma and stool samples were collected from the participants. Four female EC had been on 
short time ART due to pregnancy (three for 3.5 months, one for 14 days), all more than four 
years before study entry.  
4.2 FLOW CYTOMETRY AND VIRAL LOAD 
Determination of CD4/8+ T-cell counts and plasma HIV-1 RNA load was performed as part 
of the clinical routine with flow cytometry and CobasAmplicor (Roche Molecular Systems 
Inc., Branchburg, New Jersey, USA), respectively.  
4.3 ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS AND 
IMMUNOPHENOTYPING 
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated blood using 
Hypaque-Ficoll (GE Healthcare) density gradient centrifugation, counted with 
Nucleocounter® and finally cryopreserved at -150ºC in fetal bovine serum (Sigma-Aldrich) 
containing 10% DMSO (Sigma-Aldrich), at a concentration of 10
6
 cells/ml of 
cryopreservation media. At the analysis day, samples were thawed and PBMCs stained for 
HLA-DR and CD38 as markers of immune activation of CD4+ and CD8+ T- cells, and for 
FoxP3 and CD25 as markers of CD4+ T-regulatory cells
44
. 
4.4 MARKERS OF MICROBIAL TRANSLOCATION 
At day of sampling, plasma specimens from EDTA-treated blood were frozen at -80ºC to be 
thawed later. The samples were analysed in a blind fashion in relation to patient identity, 
clinical data and treatment response. Quantification of LPS was determined by limulus 
amebocyte assay (LAL, Lonza, Maryland, USA), according to manufacturer´s directives, but 
with modifications as described by Troseid et al
103
. LBP, sCD14 and I-FABP levels were 
assessed by enzyme-linked immunosorbent assays (ELISA) (Hycult biotech, R&D Systems, 
USA and DS Pharma Biomedical Co, Japan; respectively), according to the instructions from 
respective manufacturer. For the studies with longitudinal design, all samples from the same 
patient were assayed on the same plate. Antibody titers to flagellin levels were determined by 
an in-house anti-flagellin specific IgG ELISA
144
 using purified flagellin monomers from S. 
typhimurium (InvivoGen, USA), as it has been shown that human sera have a similar 
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recognition pattern of flagellin monomers whether isolated from flagellated E. coli or 
S.typhimurium
145
. Summarily, microwell plates (MWP) were coated overnight with purified 
flagellin from S. typhimurium (25 ng/well). Plasma samples from the study subjects were 
diluted 1:1000 and applied to the MWP the day after. After incubation and washing, the 
MWPs were incubated with HRP-conjugated antihuman IgG. Determination of total IgG 
levels was performed by commercial ELISA, following the manufacturer’s procedure 
(MABTECH, Nacka, Sweden). 
4.5 SOLUBLE MARKERS OF INFLAMMATION AND TRYPTOPHAN 
CATABOLISM 
To assess the level of inflammation in plasma, quantification of IL-6 (R&D, Minnesota, 
USA), hs-CRP (Abcam, UK), D-Dimer (Technoclone, Austria) and sCD163 (R&D) was 
done by ELISA. Plasma levels of metabolites from tryptophan catabolism were measured by 
high-performance liquid chromatography (HPLC) (http://bevital.no). All analyses were 
performed according to the manufacturers´ instructions. 
4.6 FECAL SAMPLE COLLECTION 
In paper III, the fecal samples were frozen after donation, and later stored in -70 °C. The stool 
specimens were weighed, and S.T.A.R. (Stool Transport and Recovery; Roche, Basel, 
Switzerland) buffer solution was added to each sample at a ratio of ~1 (stool) to 3 (S.T.A.R. 
buffer) within 1 month. In order to achieve homogenous suspension, the samples were 
vortexed and then stored at -80 °C before DNA extraction, as previously described
146
. In 
paper IV, a sterile tube without preservation media for fecal sampling was used when study 
participants were able to donate feces adjacent to their study visit at the out-patient clinic. The 
samples were frozen and instantly stored at -80º C. Participants who submitted feces at home 
were instead using the PSP
®
 Spin Stool DNA sampling tube (Stratec Biomedical). These 
stool samples were delivered to the clinic by the participant, or instantly sent by post and 
stored at -70
o
C according to the manufacturer´s instructions
147
.  
4.7 EXTRACTION OF DNA FROM STOOL SAMPLES 
In paper III, the stool specimens were weighed, and S.T.A.R. (Stool Transport and 
Recovery; Roche,Basel, Switzerland) buffer solution was added to each sample at a ratio of 
~1 (stool) to 3 (S.T.A.R. buffer). Samples were vortexed to achieve homogenous 
suspension and then stored at -80 °C. The frozen stool samples were thawed on ice. 
Microcentrifuge tubes(2 mL) containing 250-mg glass beads (<106 µm) were filled with a 
suspension volume of 0.5 mL of the stool sample. To achieve bacterial cell lysis, 
homogenization was performed using a MagNaLyser (Roche) twice at 2000 rpm for 40 s, 
with 40 s cooling between runs. The samples were kept cold during the rest phase to avoid 
DNA degradation due to overheating. This step was followed by centrifugation at 12 300 g 
for 5 min. The supernatant lysate solution was then transferred to a new microcentrifuge 
tube in two replicates (designated parallel A and B) for each of the samples. Fifty 
microlitres supernatant from the tubes were transferred to a KingFisher 96-well plate as 
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previously described
146
, and DNA extraction from supernatant lysate solution was performed 
using the Mag 
TM
 mini kit (LGC, Middlesex, UK). In paper IV, PowerSoil DNA Extraction 
Kit (MO BIO Laboratories, Carlsbad, CA, US) was used, following the manufacturers´ 
recommendations, respectively. 
4.8 SEQUENCING OF GUT MICROBIOTA 
In summary, the extracted DNA was amplified by PCR, with primers targeting the variable 
V3-V4 region from the bacterial 16S rRNA gene according to protocols. The amplified DNA 
products were washed to remove non-DNA material, followed by attachment of sequencing 
adapters and dual indices. The sequencing was performed on an Illumina
TM
 platform, 
generating paired-end reads of 300 bases in each direction. After a second round of cleanup, 
PCR-amplicons were quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Invitrogen, Carlsbad, MA, USA). 
4.9 SEQUENCE ANALYSIS 
In paper III, QIIME ver.1.8.0 (Quantitative Insights into Microbial Ecology) software was 
used for analyses of sequences after processing of the reads. From the full dataset, 10 000 
sequences per sample were randomly selected in order to guarantee equivalent information. 
Taxonomy classification was built on Operational taxonomic units (OTUs), requiring 97% 
cluster identity. α-diversity was calculated using number of observed species, Shannon, and 
reciprocal Simpson’s diversity indexes. To estimate the ß-diversity, principal coordinate 
analysis (PCoA) was performed, and assessments were also made with the weighted Unifrac 
and Bray–Curtis indices148, using MATLAB R2013a software (MathWorks, USA).  
In paper IV, sequencing data was processed using Mothur
149
 phylotype approach. 
Preprocessed sequences were classified using RDP algorithm
150
 in combination with 16s 
rRNA Silva database
151
. To assess α-diversity, richness and Shannon and Simpson indices 
were computed using R/vegan library
152,153
 randomly selecting subsamples of ten thousand 
counts for each subject. 
Bacterial genera count table were normalized to relative abundance measures. These were 
used to compute Bray – Curtis dissimilarity between each pair of individuals. This index was 
served as input ordination analysis using non-metric multidimensional scaling (NMDS). 
Correlation between NMDS plot axis coordinates and inflammation parameters were tested 
by applying Spearman test. Additionally, a PERMANOVA (adonis) test was performed on 
this distance matrix to partition different sources of variation using R/vegan package. 
The function of bacterial microbiome was inferred using PICRUSt
154
 on GreenGenesDB
155
 
classified phylotypes. Counts were normalized by considering 16S rRNA gene copy number. 
To infer the gene content, the normalized phylotype abundances were multiplied by the 
respective set of gene abundances, represented by Kyoto Encyclopedia of Genes and 
Genomes (KEGG) identifiers estimated for each taxon. 
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4.10 STATISTICAL ANALYSES 
4.10.1 Paper I + II 
Non-parametric statistics were applied. Two-tailed Mann-Whitney U-test was used for 
comparisons between independent groups, and Wilcoxon signed rank test for analyses of 
longitudinal paired data. Spearman´s rank test was used for determination of correlations 
between two variables. Differences in levels of MT markers between patients with or without 
antibiotics adjusted for co-variables in paper I was determined with ANCOVA. In paper II, 
differences in levels of MT markers at the different sampling points were analyzed with a 
generalized linear mixed-effects model adjusting for significant co-variables, and this model 
was based on parametric analyses. Data were analyzed by GraphPad Prism v. 5.02-04, R 
2.13.1 and STATA 12 SE/12.The significance level was set at 0.05. 
4.10.2 Paper III 
Non-parametric statistics were applied. Analyses of data between two independent groups 
were performed by two-tailed Mann-Whitney U-test, and by Wilcoxon signed rank test for 
comparisons of longitudinal samples from baseline and follow-up. α-diversity indexes were 
compared in QIIME software using a t test based on Monte Carlo permutations, whereas 
Kruskal–Wallis test was used for comparisons of ß-diversity. Correlations were analyzed 
with Spearman’s rank tests. Multivariate linear regression models included only age and sex 
as covariates because of the small sample size, and assumptions for use of the model were 
fulfilled. A two-tailed significance level of 0.05 was used. P values were corrected for 
multiple testing using false discovery rate (FDR).  The statistical analyses were performed 
with SPSS software, version 19.0.  
4.10.3 Paper IV 
Multiple group differences in diversity indices, bacterial abundances, inflammation and 
activation markers were analyzed via Kruskal–Wallis rank-based test, and Benjamini–
Hochberg correction was applied to correct for multiple testing
156
. Two-tailed Mann-Whitney 
U-test was used for comparisons of inflammation markers between two groups. 
Associations between bacterial genera, functional pathways and inflammatory markers were 
performed with Spearman´s rank test. Associations with a Benjamini–Hochberg adjusted p-
value lower than 0.01 were considered as relevant, and when plotting the heatmap, 
inflammatory parameters associated with less than two bacteria were discarded. Bacterial 
genus and functions were ordered in the heatmap using Ward hierarchical clustering.  
To evaluate the power of the classification of individuals according to the composition profile 
of their microbiome, a LASSO penalized logistic regression model was computed for each 
pair of profiles as previously described
157
. LiblineaR and pROC libraries were used to obtain 
the regression models, represent ROC curves and estimate accuracy of the model using AUC. 
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5 RESULTS 
5.1 PAPER I+II 
The detailed characteristics of HIV-1 infected subjects at baseline are presented in table 2 in 
paper I and table 1 in paper II. In summary, 71 treatment naive patients starting first line ART 
with LPV or EFV combined with two NRTIs were included in paper I. Data on use of 
antibiotics was available for 63 patients. In paper II, naive patients were starting ART with 
(n=13) or without (n=13) concomitant TMP-SMX prophylaxis. Historical data from healthy 
controls were used for comparison of levels of MT markers. 
5.1.1 Levels of LPS 
Overall LPS levels at BL were elevated in HIV-infected subjects, and declined in paper I at w 
72 in both treatment groups (Figure 4). In paper II, the BL LPS levels correlated with CD4+ 
T-cell count and were lower in the more immunocompromised (TMP-SMX) group. At one 
month (FU1), LPS levels increased in the non-TMP-SMX group, but remained unaffected as 
compared to BL in both groups after one year of ART.  
 
Figure 4. Plasma levels of LPS before and after 72 weeks of ART (paper I). 
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5.1.2 Levels of sCD14 
The BL levels of sCD14 were increased and correlated with VL in both cohorts (ρ=0.42, p= 
0.0002; ρ=0.55, p=0.005, respectively), negatively with CD4+ T-cells in paper I (ρ=-0.42, p = 
0.0003) and with LBP in paper II (ρ=0.42, p=0.03). Levels were highest in the group with 
lowest CD4+ T-cell counts (TMP-SMX), and were longitudinally reduced by initiation of 
ART in all groups of HIV-1 infected patients.  
 
5.1.3 Levels of LBP 
LBP levels were analyzed in paper II, and were elevated at BL in TMP-SMX as compared to 
non TMP-SMX group. A negative correlation (ρ= -0.65) was found at BL between LBP and 
CD4+ T-cell counts, which had a tendency to be most prominent in TMP-SMX group. LBP 
levels in TMP-SMX group were longitudinally distinctly reduced at FU2. No fluctuations in 
levels of LBP were found in the non-TMP-SMX group between BL and FU2, but this group 
had low LBP levels already at BL, almost at the same levels as the healthy controls used in 
paper IV. The reduction was still significant after adjustment for BL CD+ T-cell counts and 
viral load in the generalized linear mixed-effects model.  
 
5.1.4 Levels of anti-flagellin antibodies 
The levels of anti-flagellin IgG antibodies were assessed in paper I. All HIV-patients had 
detectable levels at BL. We found a reduction at w72, which was significant only in LPV/r 
treated individuals after stratifying the patients to their respective treatment group. Total IgG 
levels were as expected elevated at BL, and declined until w72. The ratio between of anti-
flagellin IgG and total IgG was used for verification of the reduction of specific anti-flagellin 
IgG. Also the ratio was reduced, confirming decline of anti-flagellin specific IgG and not 
only total IgG. We detected a positive correlation between LPS and anti-flagellin antibodies 
at BL and w72, but otherwise no associations with any of the other MT markers were present.  
5.1.5 Levels of I-FABP 
Also I-FABP levels were abnormally high in both cohorts at BL, with further increase at w72 
in EFV treated subjects in paper I. We also observed a temporary increase of I-FABP 
between BL and FU1 in TMP-SMX treatment arm in paper II, but after one year (FU2) there 
was no differences in I-FABP levels as compared to BL for any of the groups. After 
stratifying the subjects in paper II by type of NRTI treatment, we found that only the 15 
patients starting tenofovir (Tenofovir Disoproxil Fumarate, TDF) had elevated levels of I-
FABP at FU1. Additionally we categorized subjects upon increasing or decreasing I-FABP at 
FU1, and compared the CD4+ T-cell development in each group to investigate whether the 
transient I-FABP elevation could reflect systemic immunoreconstitution. We observed that 
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the CD4+ T cell recovery was 103 cells/µl in the group with increasing and 210 cells/µl in the 
group with decreasing I-FABP levels. 
5.1.6 Antibiotics and microbial translocation markers 
In paper I, we observed that use of antibiotics at BL (27 /71) or/and ongoing antibiotic 
treatment was associated with lower levels of sCD14 at w72 after adjusting for significant co-
variates with ANCOVA analysis.  
In paper II, levels of LBP were lower after one year in TMP-SMX treated individuals, also 
after adjusting for co-variates with the generalized linear mixed-effects model. A reduction 
was not observed in the other treatment arm with patients on ART without TMP-SMX 
treatment. As mentioned above, differential I-FABP levels were found at FU1 with elevation 
in TMP-SMX group, but this difference could not be confirmed in the multi-variate analysis. 
No difference in the kinetics of LPS or sCD14 levels was found between HIV patients on 
ART with or without concomitant use of antibiotics. 
 
5.2 PAPER III+IV 
The detailed description of the cohorts´ characteristics at BL is presented in respective Table 
1 in paper III+IV. To summarize, we included 31 HIV-1 infected individuals of whom three 
were EC, and 9 HIV-negative controls in paper III. Blood and fecal samples were obtained at 
BL and after one year. In paper IV, 48 HIV-1 infected patients and 16 HIV-seronegative 
controls were included. This was a cross-sectional study, where samples from blood and 
feces were collected at a single time point. 
 
5.2.1 Gut microbiota diversity in treatment naive patients 
5.2.1.1 α-diversity 
The α-diversity of gut microbiota represents the diversity of bacteria within each individual. 
In our cohorts, we found that the number of observed bacterial taxa was lower in HIV-
infected patients without ART as compared to seronegative controls (Figure 5), and lowest in 
the most immunocompromised patients. Further assessment with both Shannon and Simpson 
index revealed dissimilarities in the fecal microbiota between HIV patients and negative 
controls, with decreased indices in the HIV-1 infected population. We also found that 
richness estimated by indices ACE and Chao-1 was lower in HIV-infected patients with 
progressive disease (Figure 6). 
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Figure 5. Number of observed bacterial species in relation to number of analyzed sequences (paper III). 
 
 
Figure 6. Richness (genus level) and diversity indices in HIV-1 infected and negative controls (paper IV). 
 
24 
 
5.2.1.2 ß-diversity 
ß-diversity represents the inter-individual differences, heterogenecity, of fecal microbiota 
composition between different populations. Normalized bacterial counts were used for 
calculation of weighted Unifrac and Bray-Curtis dissimilarity indices, yielding highest ß-
diversity in patients with progressive HIV, and lowest in EC as compared to negative 
controls. Based upon results from calculation of ß-diversity indices, a principal coordinate 
analysis (PCoA) was performed in paper III, and non-metric multidimensional scaling 
(NMDS) and LASSO regression analysis in paper IV. The LASSO model analyses revealed 
that the composition of the gut microbiota was more different in individuals with progressive 
disease compared to negative and EC. In paper III, PCoA showed that the gut microbiota was 
overlapping between HIV progressors and negative controls, whilst the three EC were 
clustering together as presented in Figure 7. This initial observation was confirmed in paper 
IV, where the EC were clustering together in the NMDS analyses, indicating a unique gut 
microbiota composition in these individuals (Figure 8). 
 
 
Figure 7. Differences in ß-diversity between viremic patients (VP), Elite controllers (EC), and healthy controls (CTR) in PCoA  
(paper III). 
 
 
 
 25 
 
Figure 8. Clustering of Elite controllers (EC) in NMDA analysis (paper IV). 
 
5.2.2 Composition of gut microbiota in treatment naive patients 
Description of the bacterial community is built on a hierarchic ranked-based classification 
system with several taxonomic levels. In bacteriology, the highest level is phylum, followed 
by class, order, family, genus and species. We analyzed the BL fecal bacterial composition at 
several levels. In paper III, Firmicutes, Bacteroidetes, and Actinobacteria were the most 
abundant phyla, and no significant differences between HIV-1 seropositive and negative 
individuals were detected (Figure 9). Some differences were found between patients with 
progressive disease and EC, with a higher relative abundance of Actinobacteria and lower 
proportion of Bacteriodetes in HIV progressors. 
 
 
 
Figure 9. Distribution of five most abundant bacterial phyla in ART naive patients and negative controls (paper III). 
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At genus level, we found several compositional differences between HIV-infected and 
negative controls. The relative abundance of Lachnobacterium, Faecalibacterium, 
Hemophilus, Anaerofilum, Delftia, Oscillospira, Sutterella and Rhizobium was reduced, and 
proportions of Lactobacillus, Blautia and Anaerostipes were increased in HIV progressors 
compared to negative controls (Figure 10). The compositional differences between EC, HIV 
progressors and negative controls are described in paragraph 5.2.6. 
 
 
 
Figure 10. Heat map illustrating differences in bacterial genera between controls, untreated viremic HIV-1 individuals and Elite 
controllers (EC) (paper III). 
 
5.2.3 α-diversity, immune status and inflammation 
In treatment naive patients, the number of observed unique bacterial sequences in paper III 
and IV correlated to the CD4+ T-cell count in the univariate analyses (ρ=0.59, p=0.009; 
ρ=0.58, p<0.0001, respectively). After adjustment for covariates sex and age in a multivariate 
regression analysis in paper III, the independent association between the observed bacterial 
species and the CD4+ T-cell count persisted. For every gain of a bacterial species, the CD4+ 
T-cell count increased with 0.88 cells/µL. After adding a third followed by all covariates to 
the model, it was shown that only the number of observed species and LPS were 
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independently associated with CD4+ T-cell counts. The number of observed species and 
Shannon α-diversity index were negatively correlated to markers of MT (LPS, LBP), and 
soluble markers of immune activation (sCD14, sCD163, CD4/8+ T-cell ratio). We also 
observed strong negative correlations (ρ ~ -0.6) between proportions of activated CD4/8+ T-
cells and observed genera/richness indices ACE and Chao-1 in paper IV. No significant 
correlations between α-diversity and soluble markers of inflammation were found in this 
cohort. 
5.2.4 Tryptophan catabolism and gut microbiota 
The serum kynurenine/tryptophan (K/T) ratio is commonly used as a marker of IDO1 
activity, and is elevated during HIV infection
158
. Our analyses confirmed that K/T ratio is 
increased in patients with progressive HIV-1 infection, but we found no evidence of 
abnormal IDO1 activity in EC compared with negative controls. Additionally, levels of 
several metabolites from tryptophan degradation were abnormal in HIV progressors; 
xanthurenic and kynurenic acid levels were lower and anthralinic acid levels higher. 
Interestingly, K/T ratio correlated negatively to the number of observed genera and richness 
indices ACE and Chao-1. Furthermore, we observed significant correlations between NDMS 
axis 2 and tryptophan, xanthurenic acid and K/T ratio in the NMDS analysis, with a 
separation of HIV progressors from EC and negative controls, indicating a different 
tryptophan catabolism related to microbiota differences between these groups of individuals. 
At genus level, we were able to associate only Rhizobium with K/T ratio, and these were 
negatively correlated to each other. 
5.2.5 Effects of ART on gut microbiota 
ART had significant effect on the gut microbiota after longitudinal follow up. 19 patients 
were starting ART, and after almost one year the α-diversity was further reduced as compared 
to BL, with lowered number of observed species and Shannon index. In contrary, ß-diversity 
increased as a consequence of bacterial taxa changes within the individuals. The composition 
of microbiota was altered at both phylum and genus level after introduction of ART. Fecal 
proportions of genus Prevotella (phylum Bacteroides) were significantly depleted at follow 
up, and the abundance equaled that in negative controls. In phylum Firmicutes, abundance of 
genera Lachnospira, Oribacterium and Oscillospira was reduced. Finally, genus Sutterella 
(phylum Proteobacteria) was less prevalent in fecal microbiota after ART. 
5.2.6 Elite controllers 
5.2.6.1 Microbial translocation, inflammation and tryptophan catabolism 
The levels of MT markers LBP and sCD14 were low in our cohort of EC, and equal to those 
in seronegative controls. However, levels of inflammatory parameters hs-CRP and IL-6 were 
elevated in EC compared to negative controls. We found no evidence of increased cellular 
immune activation in EC as compared to controls when assessing the proportion of activated 
CD38+ HLA-DR+ CD4/8 T-cells. Plasma levels of tryptophan, the related catabolism 
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metabolites and K/T ratio were same in EC and controls, thus lower than in HIV progressors. 
All together, these data suggest that EC don´t have increased MT or immune activation, but 
persistent low-grade inflammation as compared to healthy controls. 
5.2.6.2 Gut microbiota 
Analyses of EC revealed a richer gut microbiota with higher number of observed genera and 
richness indices compared to HIV progressors, but not different from negative controls. As 
mentioned earlier, EC had less inter-individual variation of the gut microbiota composition 
than negative controls and HIV progressors, clustering together in the multidimensional 
scaling analyses PCoA and NMDS who are based on the ecological dissimilarity indices.  
Sequencing data showed that the abundance of several taxa was differential in EC. At phylum 
level, Bacteroidetes were enriched and both Proteobacteria and Actinobacteria depleted in EC 
vs HIV progressors. At genus level, Succinivibrio and Sutterella were more abundant in EC 
as compared to both HIV progressors and negative controls. Moreover, genera of Rhizobium, 
Delftia, Anaerofilum and Oscillospira were more enriched in EC vs HIV progressors, but 
were not significantly different from negative controls (Figure 11). 
 
 
 
Figure 11. Compositional differences in fecal microbiota between Elite controllers (EC), naive patients and negative controls (paper 
IV). 
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5.2.6.3 Inferred functionality of gut microbiota 
To predict the metagenomic inferred functional content of gut microbiota, PICRUSt analysis 
of gene contents was used based on the KEGG database. At the higher level II, carbohydrate 
metabolism pathway was decreased in the bacterial metagenome of EC as compared to both 
HIV progressors and negative patients. Genes encoding cardiovascular diseases and 
circulatory system pathways were instead enriched in EC as compared to HIV progressors, 
but not different from negative controls. At the more specific KEGG level III, we found that 
carbohydrate metabolism related pathways were less abundant in EC vs HIV progressors. 
These included galactose metabolism, pentose-glucoronate interconversions, pyruvate 
metabolism and pentose-phosphate pathway (PPP). Additionally, PPP was also less prevalent 
in EC vs negative controls. The predicted lipid metabolism associated pathways were mostly 
similar in EC and negative controls, and metagenomics proportions were different from HIV 
progressors. This was illustrated by lower proportions of genes encoding metabolism of fatty 
acids and lipid biosynthesis proteins in HIV progressors. EC had significantly higher 
proportions of genes involved in pathways related to synthesis and degradation of ketone 
bodies, also compared to negative controls. Anyhow, the secondary bile acid biosynthesis 
metabolism pathway, that plays an essential role in cholesterol homeostasis, was less 
represented in EC as compared to the other groups. PPAR (peroxisome proliferator-activated 
receptors)-signaling pathway, involved in metabolism of lipids, carbohydrates and proteins, 
was less abundant in HIV progressors compared with EC and controls. Bacterial genes 
involved in metabolism of tryptophan were less abundant in HIV progressors, but were 
equally abundant in EC and negative controls (Figure 12). 
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Figure 12. The metagenomic functional content of gut microbiota predicted by inferred PICRUSt analysis (paper IV).  
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6 DISCUSSION 
MT is one of the causes behind the persistent low-grade inflammation in well-treated HIV-1 
infected patients
10,159
. Most studies of MT in such patients associate the introduction of ART 
with declining levels of MT markers, but even in fully virologically suppressed patients, MT 
is significantly higher than in uninfected individuals
10,35,103,104
. 
In the first study we addressed the question whether the type of ART influences MT using the 
samples from an RCT. Our findings of a unified reduction of LPS and sCD14 after 72 weeks 
of ART in both treatment arms (NNRTI vs PI/r) are similar to previous reports
10,35,103,104,109
. 
The decreased levels of MT markers may be related to restoration of submucosal Th17+ T-
cells, enhanced epithelial cell integrity and/or recruitment of neutrophils in the gut. 
Nevertheless, LPS and sCD14 levels were still abnormally high after 1.5 years of full viral 
suppression in our study, and were actually even elevated as compared to patients with active 
inflammatory bowel disease
64,160
. 
ART was followed by declining levels of anti-flagellin IgG antibodies, but the reduction was 
significant only in LPV treated patients. We hypothesize that the choice of ART could 
directly modulate the composition of bacteria with a reduction of the number of flagellin 
containing gram-negative bacteria. It has been shown that LPV/r has an antimalarial 
activity
161
, and the older NRTI zidovudine has been found to have a direct antibacteridal 
effect on several enterobacteria, e.g. Escherichia coli and Klebsiella oxytoca
162
. Additionally, 
we have earlier shown that the levels of anti-flagellin antibodies and LPS were lower in HIV 
patients on TB-treatment in a Vietnamese cohort
89
. Alternatively, the difference may be 
explained by a more rapid restoration of the blood-gut barrier by LPV as compared to EFV.  
In opposite to the other markers, I-FABP levels did not decline in our patient populations 
during the follow-up. Actually, an increase at w72 was detected in paper I, but it remained 
significant only for EFV treated patients. In paper II, a transient I-FABP elevation was 
observed after one month, preferable in individuals with TDF containing regimen. Similarly, 
in a work by Sereti et al, patients starting very early EFV based ART (within 2-3 weeks of 
their infection) had increasing I-FABP levels during the first two weeks of treatment, which 
remained elevated after two years of viral suppression
163
. On the contrary, I-FABP levels 
were higher in a Mexican cohort of patients treated for more than five years with boosted 
atazanavir or LPV as compared to EFV treated and seronegative controls, but the cross-
sectional study design with relatively few participants limits the conclusions from this 
work
116
. As I-FABP reflects the death and turnover of enterocytes, and not directly MT, we 
speculate that the antiretrovirals themselves may have a detrimental effect on enterocytes and 
suggest that I-FABP has a limited value as estimator of MT. 
As antibiotics modulate the diversity and composition of the gut microbiota
164,165
, we studied 
the influence of antibiotics on the level on MT markers in cohorts I and II. Use of TMP-SMX 
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as Pneumocystis jirovecii prophylaxis is recommended to HIV-patients with a CD4+ T-cell 
count <200/µL, and is frequently started in combination with ART. This antibiotic has a 
broad antibacterial spectrum, covering both gram-negative and –positive organisms, and is 
also active against the opportunistic agent Toxoplasma gondii. In the paper I, we found that 
levels of sCD14 were significantly lower at week 72 in patients using antibiotics at BL or in 
those with ongoing antibiotic treatment, but no effect of antibiotics on any of the other MT 
markers was observed. Serving as a marker of macrophage/monocyte activation upon a wider 
range of microbial stimuli and not as a direct marker of MT, levels of sCD14 may better 
represent the overall innate host response to gut-resident microbial triggers. The importance 
of sCD14 as an important predictive marker has previously been demonstrated when the 
mortality risk of HIV infected individuals has been independently correlated to plasma levels 
of sCD14
36
.  
In study II, levels of sCD14 tended to be higher in TMP-SMX group at BL, but in this set of 
patients we could not confirm the antibiotics’ effect on sCD14 at FU2 after one year. On the 
other hand we found that LBP levels were significantly reduced in the group of TMP-SMX 
treated patients suggesting additional antibiotic effect. Surprisingly BL LPS levels were 
lower in TMP-SMX group, and no longitudinal alternations in LPS levels were observed at 
all until end of study. This may reflect that 8/13 patients in this group received antibiotics or 
antifungals within 6 months from BL, with a compositional shift in the gut microbiome from 
gram-negative to gram-positive bacteria including Firmicutes
166
, altered proportions of fungal 
organisms
63
 or viruses such as Adenoviridae and Anelloviridae
167
 as suggested by others. 61.5 
% of TMP-SMX patients had stopped prophylaxis at FU2, and this might have influenced the 
longitudinal development of LPS levels due to TMP-SMX related alternations in the 
composition of gut microbiota, which at least partially was inversed when the prophylaxis 
was completed. LBP induction may origin from bacteria, fungi but also viruses
168
, and 
elevation of LBP levels in the more immunosuppressed group may be caused by LBP release 
induced by broader microbial triggers. LBP elevation due to IRIS during HIV/TBC co-
infection has also been reported
169
. The reduction of LBP levels in the univariate analysis was 
further confirmed with multivariate analysis. As the results were divergent between LBP and 
LPS, and LPS detection could be substantially influenced by microbiome shifts and 
methodological issues
170
, we suggest that LBP is a more appropriate marker of MT than LPS. 
As our first two studies strongly imposed that MT may be affected by alterations in the gut 
microbiota, we proceeded with analyses of the fecal bacterial composition in different HIV 
populations; HIV progressors and EC. We were able to show that the α-diversity in treatment 
naive HIV progressors is significantly reduced as compared to seronegative controls, 
similarly to work by others 
134,171,172
. The lowest number of bacterial species was detected in 
the most immunodeficient patients and we could report the novel finding that the α-diversity 
of gut microbiota is positively correlated number of CD4+ T-cells. The inter-individual 
diversity was highest in HIV progressors, lower in controls and lowest in EC. This followed 
observations from e.g. Mutlu et al, who showed a more dispersed distribution of fecal 
microbiota samples in HIV-infected as compared to negative controls
134
. 
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Others have described dysbiosis in HIV patients , with enrichment of phylum Proteobacteria 
and depletion of Bacteriodetes, Firmucutes and family Ruminococcaceae and 
Lachnospiraceae
114,115,134,171,162
. We found significant depletion of Lachnobacterium (phylum 
Lachnospiraceae), Faecalibacterium (Ruminococcaceae), Hemophilus, Delftia, Sutterella, 
Rhizobium (Proteobacteria), Anaerofilum, Oscillospira (Firmicutes) at genus level in HIV 
progressors. Several of these genera exhibit immunomodulatory capacities which may disturb 
the enteric homeostasis. For instance, Faecalibacterium is a major producer of the SCFA 
butyrate, which promotes differentiation of regulatory T-cells in colon
173
. Sutterella has been 
linked to fecal IgA-levels, and may affect differentiation of  Th17+ cells
174,175
, and members 
of Rhizobium are able to convert tryptophan to indole-3-aceticacid
176
, a metabolite that may 
reduce Th17+ cells and IL-22 production
177,178
.  Genus Lactobacillus, Blautia and 
Anaerostipes were all more abundant in HIV progressors vs negative controls, but Prevotella 
genus was not enriched in our cohort as described by others
132,133,166
. Still, the abundance of 
Prevotella was decreasing in HIV progressors after receiving ART for one year. 
Interestingly, we could determine taxa differences between the three EC and HIV 
progressors. Phylum Bacteroidetes was less and both Proteobacteria and Actinobacteria more 
abundant in HIV progressors compared with EC.  
Due to the low number of included EC in the third study, we aimed to expand our 
observations of the compositional gut microbiota differences in a larger EC cohort, 
additionally addressing the metabolic functionality of fecal microbiota. Compared with HIV 
progressors and negative controls, EC had a higher relative abundance of two genera:  
Succinivibrio and Sutterella. We hypothesize that these genera are of special interest and 
important contributors to immunological control mechanisms in EC, even though their 
relative abundance is low, only about 0.05-0.5%.Thus, we found a significant positive 
correlation between proportions of Sutterella and CD4+ T-cell counts, and negative 
association to markers of CD4/8+ T-cell activation. Depletion of Sutterella has been observed 
in gut microbiota during other conditions where the adaptive immune system is involved, e.g. 
in multiple sclerosis and in lymphoma patients after bone marrow transplantation
179,180
. 
Genus Succinivibrio may be of even more interest, given that we were able to show that 
initiation of ART was followed by enrichment of Succinivibrio in study III. Additionally, 
others have demonstrated that production of metabolites by members of Succinivibrionaceae 
was associated with immune recovery after initiation of ART, thus giving a mechanistic 
explanation behind the relation between abundance of Succinivibrio and its immunological 
effects
181
. 
A differential abundance of four genera was found between EC/negative controls and HIV 
progressors; Rhizobium, Delftia, Anaerofilum and Oscillospira were all depleted in HIV 
progressors. Only one genus, Rhizobium, correlated with K/T ratio suggesting that these 
bacteria may be key modulators in microbiota related tryptophan catabolism. As described 
above, Rhizobia produce the immunomodulatory catabolite indole-3-acetic acid affecting 
levels of IL-17/22, and should affect the mucosal levels of tryptophan. A lower abundance of 
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these bacteria may be followed by higher intraluminal concentrations of tryptophan, causing 
induction of IDO1 from gut resident macrophages, leading to lower serum tryptophan 
concentrations and higher K/T ratio that we observed in our analyses. This may also be 
mirrored in the functional analyses, where we found the inferred metagenomic abundance of 
tryptophan metabolism pathway was reduced in gut microbiota of HIV progressors as 
compared to EC and negative controls. CD4/8 T-cell ratio may be used as a marker of 
immune activation, higher ratio reflects less activation. Fecal depletion of genus Oscillopira 
has been associated to the inflammatory Crohn`s disease and obesity
182,183
, and it has been 
speculated that Oscillopira probably may produce the  SCFA butyrate
184
. In our HIV cohort, 
abundance of genus Oscillopira was strongly positively correlated to CD4/8 T-cell ratio, and 
negatively to activated (HLA-DR+) CD4/8+ T-cells, and thus lower abundance of this taxa 
seems to be causing immune activation also in HIV-1 infection. Low abundance of genus 
Anaerofilum has been related to higher intestinal permeability
185
, and may in our cohort 
contribute to the abnormal MT observed in HIV progressors. 
Inferred functional analysis of gut metagenome with PICRUSt revealed very intriguing 
differences between HIV progressors, EC and negative controls. The proportion of bacterial 
genes encoding pathways involved in metabolism of carbohydrates was significantly lower in 
EC. More specifically, pentose phosphate pathway, glucoronate interconversions-, and 
pyruvate metabolism pathways related genes were less represented in EC compared to HIV 
progressors and negative controls. Also bacterial galactose metabolism was lowest in EC, but 
this difference remained significant only against HIV progressors. In contrary, we were able 
to observe that proportion of genes involved in metabolism of lipids and fatty acids was 
lowest in HIV progressors, with exceptions of secondary bile acid biosynthesis pathway, 
which was depleted in EC but not different between HIV progressors and controls. Also 
PPAR (peroxisome proliferator-activated receptors)-signaling pathway, which has a major 
role in metabolism of fatty acids and lipids but also carbohydrates and proteins
186
, was 
significantly reduced in HIV progressors. In contrary, lineolic acid metabolism pathway was 
enriched in HIV progressors. This is a long-chain essential fatty acid, precursor of 
arachidonic acid, which may prevent lymphoproliferation and downregulate adaptive 
immune cells
187
. 
Based on our results, we theorize that the bacterial composition and function of gut 
microbiota upon metabolism of lipids, carbohydrates and other nutrients interfere with and 
shape the enteric part of the host’s immune system. The bacterial genomic pool in EC seems 
to be unique, favoring metabolism of lipids and with lower bacterial proportions involved in 
metabolism of carbohydrates and secondary bile acids. This is of extraordinary interest, as 
intracellular metabolic pathways involved in carbohydrate and lipid metabolism are important 
regulators of both innate and adaptive immune cells
188
. If the gut microbiota in EC is of 
importance for maintaining the immunological and sustained viral control in these patients, 
therapeutic interventions such as transplantation of bacteria with immunomodulatory effects 
could be one way to proceed to reduce immune activation and inflammation in HIV-1 
infection. 
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Fecal microbiota transplantation (FMT) has also been considered as a therapeutic option in 
diseases accompanied by gut microbiota dysbiosis and MT. Mb Crohn`s disease and 
ulcerative colitis are featured by structural damage in the gut wall originating from 
autoimmune inflammation, and an abnormal shift in the gut microbiome is found during both 
active and inactive disease. A successful attempt to achieve clinical remission and endoscopic 
improvement with FMT in an otherwise treatment refractory patient with Mb Crohn was 
recently reported
189
, and remission rates after FMT in patients with ulcerative colitis 
diagnosed within one year before intervention were superior as compared to more durable 
disease in a randomized study
190
. These findings warrant more randomized studies in IBD 
field. FMT as a therapeutic option in metabolic diseases with dysbiotic gut microbiota like 
diabetes type 2 and obesity has also been proposed as a plausible way to approach alternative 
treatments for these conditions
191
. For instance, allogenic FMT from lean donors was 
followed by increased peripheral insulin sensitivity for a period of 6 weeks in patients with 
hypermetabolic syndrome
192
, and several clinical studies on FMT as treatment of obesity are 
ongoing (www.clincaltrials.gov). 
We acknowledge that all results from gut microbiota studies are influenced by external 
factors. Diet, intake of antibiotics and alcohol all have a major impact
165,193-195
, and both  
sexual practices and exercise modulate the composition and functionality of gut 
microbiota
196,197
. Travelling has also been associated with rapid shifts in microbiota 
composition
198
. Additionally, acute conditions like gastroenteritis and many chronic diseases 
may all contribute to alternations of microbiota. All of these confounding factors are seldom 
considered in reports from microbiome studies due to the complexity behind these metadata. 
This may to some extent explain why the results from gut microbiota analyses from different 
populations and studies are not unified. 
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7 CONCLUSIONS 
HIV-1 infected individuals have elevated levels of microbial translocation (MT) markers, 
with the exception of Elite controllers. Introduction of ART is followed by declining levels of 
MT, though not normalized under long term follow up (up to 72 weeks). The choice of ART 
regimen affects the kinetics of some MT markers. Concomitant use of ART and antibiotics 
seems to have an additional impact on microbial translocation. 
Moreover, we show that gut microbiota dysbiosis features HIV-1 infection, with lower 
number of represented taxa and reduced intraindividual (α-) diversity. Furthermore, CD4+ T-
cell counts and α-diversity are positively correlated in untreated subjects. The inter-individual 
differences (ß-diversity) are highest in HIV-1 patients with progressive disease, whereas the 
gut microbiota variability in Elite controllers is much lower, and the gut bacterial 
composition in these patients is different from other HIV-1 infected patients. 
Abundance of several taxa is altered in HIV-1 infected as compared to negative controls, 
furthermore differences are present also between EC and other HIV-1 infected individuals. 
Following ART, α-diversity is further reduced and composition modified at genus level. 
Functional analyses of the gut bacterial metagenome reveal that Elite controllers have a 
unique enteric metabolic profile. Bacterial genes encoding carbohydrate metabolism 
pathways are less abundant compared to both other HIV-subjects and negative controls. 
Additionally, abundance of pathways related to metabolism of lipids and fatty acids are 
different in EC from HIV-1 progressors. As metabolites from bacterial digestion of nutrients 
are deeply involved in the development and control of the human immune system, we suggest 
that the gut microbiota in Elite controllers may be one of the factors involved in the sustained 
virological and immunological control observed in this minor set of HIV-1 infected 
individuals. We also propose that fecal microbiota modulation by supplementation of 
pre/probiotics or fecal microbiota transplantation may have positive influence on 
inflammation related HIV pathogenesis in treated HIV-1 patients. 
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8 FUTURE PLANS AND PERSPECTIVES 
 
The data in this doctoral thesis confirm that microbial translocation features HIV-1 infection 
even in well treated individuals, and that the bacterial composition and its inferred 
functionality are profoundly altered as compared to uninfected individuals. Additionally, the 
gut microbiota in Elite controllers is different from both uninfected and other HIV infected 
subjects. 
 
As metagenomics analyses suggest that the relation between carbohydrate and lipid 
metabolism is differential in Elite controllers controlling their infection, further metabolomics 
studies are warranted in order to estimate the levels of fecal metabolites, e.g. tryptophan 
catabolites, in the different populations. If such differences are confirmed, it should be 
explored in what specific mechanisms these metabolites modulate immune cells. One way to 
proceed could be to investigate the transcriptome of immune cells like CD4/8+ T-cells, B-
cells and innate immune cells, and correlate the transcriptome to differential bacterial taxa or 
metabolites. 
 
Additionally, we found that the richness of the gut microbiota was inversely correlated to K/T 
ratio, which reflects IDO1 activity that is contributing to hyperinflammation. So far, most 
interventional studies on probiotics supplementation have focused on suspensions containing 
single or very few bacterial species. Our observation indicates that alternative therapeutic 
interventions modulating gut microbiota richness and not only composition are warranted in 
order to reduce HIV-related inflammation. 
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9 SAMMANFATTNING PÅ SVENSKA 
Trots effektiv behandling med bromsmedicinering kvarstår en kronisk aktivering av 
immunförsvaret samt låggradig inflammation vid HIV-1 infektion. En viktig mekanism som 
driver inflammationen är s.k. mikrobiell translokation (MT). Detta innebär att delar från 
tarmens bakterier, svamp eller parasiter läcker över en av HIV skadad tarm-blod barriär. De 
mikrobiella komponenterna aktiverar i kroppen både det medfödda och förvärvade 
immunförsvaret. Detta återföljs av ökad inflammation som anses bidra till den förhöjda risk 
för sena komplikationer i form av t.ex. hjärt-kärlsjukdom, maligniteter och kognitiva 
funktionsnedsättningar som observerats hos HIV-patienter. 
Syftet med detta doktorandprojekt har varit att studera hur insättande av olika 
bromsmediciner påverkar graden av MT, samt även hur samtidig användning av antibiotika 
påverkar MT. Därtill även att undersöka tarmflorans sammansättning vid obehandlad HIV-1 
infektion, samt efter insatt bromsmedicinering. Slutligen ville vi även kartlägga tarmflorans 
sammansättning samt biologiska funktionalitet hos s.k. Elite controllers, sällsynta HIV-1 
patienter som utan bromsmedicinering själva kan kontrollera sitt virus och upprätthålla 
normalt immunförsvar i upp mot 30 år. 
I delarbete I, en randomiserad klinisk studie, startade obehandlade HIV-1 patienter 
bromsmedicinering baserad på efavirenz eller lopinavir. Blodmarkörer för MT var förhöjda 
innan behandling, sjönk efter 72 veckor men var även då förhöjda jämfört med historiska 
friska kontrollpersoner. Vissa skillnader beträffande nivån på MT markörer observerades 
mellan de olika typerna av bromsmedicinering. Därutöver påvisades också en signal 
indikerande att antibiotika gynnsamt påverkade aktiveringen av det medfödda 
immunförsvaret. Resultaten från denna studie talar för att val av HIV preparat, samt 
eventuellt också användning av antibiotika kan ha betydelse för inflammationsutvecklingen 
hos HIV-1 patienter på sikt.  
I delarbete II påbörjade obehandlade HIV-1 patienter bromsmedicinering med eller utan 
samtidig trim-sulfa behandling (antibiotika förebyggande mot Pneumocystis jirovecii 
lunginflammation). Även här konstaterades förhöja markörer för MT i blod innan behandling. 
Patienter som erhöll samtidig behandling med trim-sulfa hade en bättre nedgång av vissa MT 
markörer, även efter justering för relevanta variabler som grad av immundefekt (antal CD4+ 
celler) och HIV-1 virusmängd i blod. Resultaten i detta arbete antyder att antibiotika-
användning kan påverka markörer för MT, vilket man bör beakta vid tolkning av studier som 
undersöker MT vid HIV-1 infektion. 
I delarbete III kartlades den bakteriella tarmfloran hos HIV-1 patienter med 16S rRNA-
sekvensering innan, samt efter knappt ett års behandling med bromsmedicinering. 
Obehandlade patienter uppvisade en lägre bakteriell diversitet (artrikedom) i tarmen, mätt 
som antal samt proportioner av påvisade arter hos den enskilde individen (alfa-diversitet), 
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samt därutöver återfanns även en ökad variation av arter på gruppnivå (beta-diversitet). Efter 
påbörjad bromsmedicinering kunde ingen förbättring av diversiteten iakttas. Alfa-diversiteten 
var direkt korrelerad till immunstatus mätt som antal (CD4+) immunceller i blod. Flertalet 
skillnader mellan HIV-1 infekterade och friska kontrollpersoner observerades både på 
bakteriers släkt- och artnivå, med bl a ökad förekomst av Lactobaciller och minskad frekvens 
av Lachnobacterium, Faecalibacterium och Hemophilus hos HIV-1 infekterade. Detta arbete 
visar att förändringar av tarmfloran kan kopplas till grad av immundefekt vid HIV-1 
infektion, och att förändringarna i tarmfloran består trots nästan ett års behandling med 
bromsmediciner.  
I delarbete IV undersöktes den bakteriella tarmflorans sammansättning och funktionalitet 
baserat på 16S rRNA-sekvensering med PICRUSt analys hos 16 HIV-1 infekterade Elite 
controllers, hos HIV-1 infekterade med normalt framskridande sjukdom samt HIV negativa 
kontroller. Till skillnad från övriga HIV-1 infekterade hade Elite controllers tarmflora samma 
alfa-diversitet som och även störst likhet med floran hos HIV negativa kontrollpersoner. Flera 
bakteriella släkten var överrepresenterade i tarmfloran hos Elite controllers jämfört med 
övriga, såsom Sutterella samt Succinivibrio, och även flertalet skillnader mellan Elite 
controllers och övriga HIV-1 infekterade kunde identifieras. Vid funktionsanalys av 
tarmfloran konstaterades att den bakteriella andelen av floran som är inblandad i metabolism 
av kolhydrater var lägre hos Elite controllers, medan dessa individer istället hade en högre 
andel bakterier inblandade i metabolism av fetter och olika fettsyror jämfört med övriga HIV-
1 infekterade. Denna studie visar således att Elite controllers har en unik tarmflora med en 
funktionalitet som avviker både från övriga HIV-1 infekterade samt HIV negativa 
kontrollpersoner. Detta kan möjligen bidra till dessa individers förmåga till att upprätthålla en 
långvarig egenkontroll av HIV-infektionen. 
 
Sammanfattningsvis visar avhandlingens studier att bromsmedicinering och eventuellt 
antibiotika minskar graden av MT, samt att val av bromsmedicinering kan vara av betydelse. 
Dessutom har HIV-1 infekterade individers tarmflora en avvikande sammansättning och 
funktion, men Elite controllers skiljer sig från övriga HIV-1 infekterade då de besitter en unik 
tarmflora som möjligen bidrar till deras långvariga kontroll av HIV-1 infektionen. 
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